title: Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme.
abstract: Dendritic cells (DCs) are potent antigen presenting cells and play critical role in T cell-mediated immunity. DCs have been shown to induce strong anti-tumor responses both in vitro and in vivo. Their efficacies in tumor therapy are being investigated in clinical trials. Previous evidence has shown that these DCs enhance the cytotoxicity of NK cells. We generated NK-like T cells (CD3(+)CD56(+)), a novel type of effector cells differentiated from normal lymphocyte, which is now being used for adoptive immunotherapy in clinical trials. This study aimed to elucidate the effects of NK-like T cells after co-culturing with DCs against tumor cells. The result revealed that tumor-derived RNA-pulsed DCs can enhance the immune responses of NK-like T cells against glioblastoma multiforme cell line but these effector cells did not appear to have the cytotoxic effect against normal cells (human umbilical vein endothelial cells (HUVEC) and fibroblasts) in vitro. This study may be beneficial for the development of new immunologic effector cells for using in adoptive immunotherapy for glioblastoma multiforme in the future.
authors.affiliation: Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.
authors.forename: Prachya
authors.initials: P
authors.lastname: Vichchatorn
authors.forename: Adisak
authors.initials: A
authors.lastname: Wongkajornsilp
authors.forename: Sawang
authors.initials: S
authors.lastname: Petvises
authors.forename: Sumalee
authors.initials: S
authors.lastname: Tangpradabkul
authors.forename: Samart
authors.initials: S
authors.lastname: Pakakasama
authors.forename: Suradej
authors.initials: S
authors.lastname: Hongeng
mesh_terms: D017951:Antigen Presentation; D017252:CD3 Complex / Q000276:immunology; D019002:CD56 Antigen / Q000276:immunology; D002460:Cell Line; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology*; D042783:Endothelial Cells / Q000166:cytology; D004730:Endothelium, Vascular / Q000166:cytology; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology*; D012334:RNA, Neoplasm; D013601:T-Lymphocytes / Q000276:immunology*; D014471:Umbilical Veins / Q000166:cytology
chemical_list: D017252:CD3 Complex; D019002:CD56 Antigen; D012334:RNA, Neoplasm